Pila Pharma
Business Services · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Norra Vallgatan 72 / 211 22, Malmoe, Ska...Website
www.pilapharma.comRevenue
$5.5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Pila Pharma
Pila Pharma AB is a clinical stage biotech company focused on developing XEN-D0501, a selective TRPV1 antagonist aimed at treating type 2 diabetes and erythromelalgia. The company is pioneering an oral solution for obesity and diabetes, targeting a significant market with over 1 billion individuals affected by obesity. Pila Pharma aims to provide innovative treatments that differ from existing therapies, emphasizing the importance of oral solutions in addressing global health challenges. Their ongoing research and development efforts are supported by a strong commitment from investors, highlighting the potential for significant market impact.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pila Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Pila Pharma launches new products
Funding: Get notified immidiatlly once Pila Pharma has new funding data
Pila Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Pila Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Pila Pharma
Check if Pila Pharma has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Pila Pharma is spiking on competitors!
Earning: See what the market has to say on Pila Pharma recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Pila Pharma as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Pila Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Pila Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Pila Pharma.
Pila Pharma financials insights
Gather financial insights about Pila Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Other Financing Round
$963K
Pila Pharma Tech Stack
A closer look at the technologies used by Pila Pharma
See more technologies
Most Recent Scoops
Project
Pila Pharma has paused its clinical study plans in erythromelalgia pending the outcome of PPCT 04 Part One, with the intent to progress a smaller pilot study in erythromelalgia to assess potential pain alleviation once a therapeutic window is established. The company holds an FDA Orphan Drug Designation for the treatment of erythromelalgia.
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Pharmaceuticals, Clinical Operations, Regulations
Funding
Funding
Funding
Pila Pharma News & Media
BioStock: Pila Pharma’s CEO comments on the Q2 report
Malmö-based biotech company Pila Pharma advances towards clinical phase II studies with XEN-D0501 at a steady pace. During the second quarter of 2022 the company announced plans to enter a new indication with the drug candidate. BioStock asked the company’s CEO Dorte X. Gram about her views on the second quarter and about the plans ahead. Read the full article at biostock.se: https://www.biostock.se/en/2022/08/pila-pharmas-ceo-comments-on-the-q2-report/ This is a press release from BioStock - CoBioStock: Discovery behind Pila Pharma’s leading principle receives Nobel Prize
The 2021 Nobel Prize in Medicine went to David Julius and Ardem Patapoutian for their discoveries of the body’s receptors for temperature and touch. The principle behind the Nobel Laureates’ discovery can be found at the Malmö-based biotech company Pila Pharma, which has further researched the TRPV1 receptor to develop a treatment for type 2 diabetes. BioStock contacted the company’s CEO Dorte X Gram to get her view on the fact that the discoveries have
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Pila Pharma
Sign Up For FreeTo access detailed company insights
Pila Pharma AB is a clinical stage biotech company focused on developing XEN-D0501, a selective TRPV1 antagonist aimed at treating type 2 diabetes and erythromelalgia. The company is pioneering an oral solution for obesity and diabetes, targeting a significant market with over 1 billion individuals affected by obesity. Pila Pharma aims to provide i... Read More
